Zura Bio FY2025 EPS Forecast Decreased by Cantor Fitzgerald

Zura Bio Limited (NASDAQ:ZURA - Free Report) - Equities research analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for Zura Bio in a research note issued on Wednesday, March 26th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will earn ($0.45) per share for the year, down from their previous forecast of ($0.40). Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Zura Bio's current full-year earnings is ($0.65) per share.

Zura Bio (NASDAQ:ZURA - Get Free Report) last posted its quarterly earnings results on Tuesday, March 25th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.09. The business had revenue of $0.00 million for the quarter.

A number of other brokerages have also commented on ZURA. Chardan Capital cut their price target on shares of Zura Bio from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, March 26th. Guggenheim reaffirmed a "buy" rating and set a $15.00 target price on shares of Zura Bio in a report on Wednesday, March 26th. Oppenheimer reiterated an "outperform" rating and issued a $19.00 price target (down previously from $20.00) on shares of Zura Bio in a research report on Wednesday, March 26th. Finally, HC Wainwright restated a "neutral" rating and set a $5.00 price objective on shares of Zura Bio in a research report on Tuesday, December 24th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $15.00.

Remove Ads

Zura Bio Stock Performance

Shares of ZURA traded up $0.03 during trading hours on Friday, reaching $1.30. The stock had a trading volume of 168,733 shares, compared to its average volume of 376,592. Zura Bio has a 12 month low of $1.07 and a 12 month high of $6.35. The stock has a market capitalization of $84.56 million, a PE ratio of -2.46 and a beta of 0.06. The company's 50-day moving average is $1.46 and its two-hundred day moving average is $2.72.

Institutional Trading of Zura Bio

Institutional investors and hedge funds have recently modified their holdings of the business. Charles Schwab Investment Management Inc. grew its position in Zura Bio by 51.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 291,807 shares of the company's stock valued at $1,185,000 after buying an additional 98,972 shares during the period. The Manufacturers Life Insurance Company bought a new stake in shares of Zura Bio in the third quarter valued at approximately $71,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Zura Bio during the 3rd quarter valued at approximately $46,000. MetLife Investment Management LLC bought a new position in Zura Bio in the 3rd quarter worth approximately $111,000. Finally, Braidwell LP purchased a new position in Zura Bio in the 3rd quarter valued at approximately $10,040,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.